Given the rapid introduction of novel endocrine agents and antibody–drug conjugates (ADCs) into the therapeutic landscape, the successful development of novel agents targeting the cell cycle will likely require robust anti‐tumour activity, manageable toxicity and, in contrast to the initial use of CDK4/6i in combination with ET, biomarker enrichment. The gene discussed is CDK4; the disease is neoplasm.